PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

NEW YORK, May 27, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players
http://www.reportlinker.com/p01190414/PharmaPoint-Pediatric-Respiratory-Syncytial-Virus-RSV-Prophylactics---Current-and-Future-Players.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=General_Medicine_and_Specialty_Medicine

PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

Summary

GlobalData has released its pharma report, "PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players". The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing RSV Market. The report identifies and analyses the key companies shaping and driving the global RSV market. The report provides insight into the competitive RSV landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by GlobalData's team of industry experts.

Scope

- Investigation of current and future market competition for RSV
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of the RSV sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving the RSV Market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What's the next big thing in the global RSV market landscape? Identify, understand and capitalize

Table of Contents

1 Table of Contents 7
1.1 List of Tables 9
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
3 Market Outlook 11
3.1 US 11
3.1.1 Forecast 11
3.1.2 Key Events 13
3.1.3 Drivers and Barriers – Global Issues 13
4 Current and Future Players 18
4.1 Overview 18
4.2 Trends in Corporate Strategy 19
4.3 Company Profiles 21
4.3.1 AstraZeneca (MedImmune) 21
4.3.2 Novavax 23
5 Appendix 26
5.1 Bibliography 26
5.2 Abbreviations 27
5.3 Methodology 28
5.4 Forecasting Methodology 28
5.4.1 Number of eligible patients for prophylaxis 28
5.4.2 Utilization rates of Synagis 29
5.4.3 Patient share and generic erosion 30
5.4.4 Weight of high risk infants 30
5.4.5 Cost per day 30
5.4.6 Number of prophylaxis days per year 30
5.4.7 Annual cost of therapy 31
5.4.8 Patient compliance 31
5.4.9 Total sales 31
5.4.10 Drugs Included in Each Therapeutic Class 31
5.4.11 Launch and Patent Expiry Dates 31
5.4.12 General Pricing Assumptions 32
5.4.13 Individual Drug Assumptions 32
5.5 Physicians and Specialists Included in this Study 33
5.6 About the Authors 34
5.6.1 Authors 34
5.6.2 Epidemiologist 35
5.6.3 Global Head of Healthcare 35
5.7 About GlobalData 36
5.8 Contact Us 36
5.9 Disclaimer 36

List of Tables

Table 1: US Sales Forecasts ($m) for Synagis, 2012–2022 12
Table 2: Key Events Impacting Sales for RSV Prophylactics in the US, 2012 13
Table 3: Pediatric RSV Market – Drivers and Barriers, 2012 13
Table 4: Key Companies in the Pediatric RSV Prophylactic Market – United States, 2012 18
Table 5: AstraZeneca's RSV Prophylactics Portfolio Assessment, 2013 22
Table 6: AstraZeneca SWOT Analysis, 2012 22
Table 7: Novavax's Pediatric RSV Prophylactics Portfolio Assessment, 2012 24
Table 8: Novavax SWOT Analysis, 2012 25
Table 9: Key Launch Date 31
Table 10: Key Patent Expiries 31

List of Figures

FiguRe 1: Company Portfolio Gap Analysis in Pediatric RSV, 2012–2022 18

Companies Mentioned
AstraZeneca (MedImmune)
Novavax

To order this report:
General_Medicine_and_Specialty_Medicine Industry: PharmaPoint: Pediatric Respiratory Syncytial Virus (RSV) Prophylactics - Current and Future Players

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker